期刊文献+

MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma 被引量:5

MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma
下载PDF
导出
摘要 AIM: To compare the diagnostic capability of multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) for the detection of hepatocellular carcinoma (HCC) tumour nodules and their effect on patient management. METHODS: A total of 28 patients (25 male, 3 female, mean age 67 ± 10.8 years) with biopsy-proven HCC were investigated with 64-row MDCT (slice 3 mm native, arterial and portal-venous phase, 120 mL Iomeprol, 4 mL/s, delay by bolus trigger) and MRI (Tlfs fl2d TE/ TR 2.72/129 ms, T2tse TE/TR 102/4000 ms, 5-phase dynamic contrast-enhanced Tlfs fl3d TE/TR 1.56/4.6, Gadolinium-DTPA, slice 4 mm). Consensus reading of both modalities was used as reference. Tumour nodules were analyzed with respect to number, size, and location. RESULTS: In total, 162 tumour nodules were detected by consensus reading. MRI detected significantly more tumour nodules (159 vs 123, P 〈 0.001) compared to MDCT, with the best sensitivity for early arterial phase MRI. False-negative CT findings included nodules ≤ 5 mm (n = 5), ≤ 10 mm (n = 17), ≤ 15 mm (n= 12),≤20mm(n=4),andlnodule〉20mm.MRI missed 2 nodules ≤ 10 mm and 1 nodule ≤ 15 mm. On MRI, nodule diameters were greater than on CT (29.2 ≤25.1 mm, range 5-140 mm vs 24.1 ± 22.7 mm, range 4-129 mm, P 〈 0.005). In 2 patients, MDCT showed only unilobar tumour spread, whereas MRI revealed additional nodules in the contralateral lobe. Detection of these nodules could have changed the therapeutic strategy. CONCLUSION: Contrast-enhanced MRI is superior to 64-row MDCT for the detection of HCC nodules. Patients should be allocated to interventional or operative treatment according to a dedicated MRI-protocol. AIM:To compare the diagnostic capability of multidetector computed tomography(MDCT) and magnetic resonance imaging(MRI) for the detection of hepatocellular carcinoma(HCC) tumour nodules and their effect on patient management.METHODS:A total of 28 patients(25 male,3 female,mean age 67±10.8 years) with biopsy-proven HCC were investigated with 64-row MDCT(slice 3 mm native,arterial and portal-venous phase,120 mL Iomeprol,4 mL/s,delay by bolus trigger) and MRI(T1fs fl2d TE/ TR 2.72/129 ms,T2tse TE/TR 102/4000 ms,5-phase dynamic contrast-enhanced T1fs fl3d TE/TR 1.56/4.6,Gadolinium-DTPA,slice 4 mm).Consensus reading of both modalities was used as reference.Tumour nodules were analyzed with respect to number,size,and location.RESULTS:In total,162 tumour nodules were detected by consensus reading.MRI detected signifi cantly more tumour nodules(159 vs 123,P<0.001) compared to MDCT,with the best sensitivity for early arterial phase MRI.False-negative CT findings included nodules ≤5 mm(n=5),≤10 mm(n=17),≤15 mm(n=12),≤20 mm(n=4),and 1 nodule >20 mm.MRI missed 2 nodules ≤10 mm and 1 nodule ≤15 mm.On MRI,nodule diameters were greater than on CT(29.2±25.1 mm,range 5-140 mm vs 24.1±22.7 mm,range 4-129 mm,P<0.005).In 2 patients,MDCT showed only unilobar tumour spread,whereas MRI revealed additional nodules in the contralateral lobe.Detection of these nodules could have changed the therapeutic strategy.CONCLUSION:Contrast-enhanced MRI is superior to 64-row MDCT for the detection of HCC nodules.Patients should be allocated to interventional or operative treatment according to a dedicated MRI-protocol.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第48期6044-6051,共8页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献3

二级参考文献181

  • 1Kazutaka Kurokohchi,Seishiro Watanabe,Tsutomu Masaki,Naoki Hosomi,Yoshiaki Miyauchi,Takashi Himoto,Yasuhiko Kimura,Seiji Nakai,Akihiro Deguchi,Hirohito Yoneyama,Shuhei Yoshida,Shigeki Kuriyama.Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(10):1426-1432. 被引量:29
  • 2[1]Parkin DM,Bray F,Ferlay J,Pisani P.Estimating the world cancer burden:Globocan 2000.Int J Cancer 2001; 94:153-156 被引量:1
  • 3[2]Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma.Lancet 2003; 362:1907-1917 被引量:1
  • 4[3]Fattovich G,Giustina G,Realdi G,Corrocher R,Schalm SW.Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa.European Concerted Action on Viral Hepatitis (EUROHEP).Hepatology 1997; 26:1338-1342 被引量:1
  • 5[4]Kao JH,Chen DS.Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia.Liver Int 2005;25:696-703 被引量:1
  • 6[5]Bruno S,Silini E,Crosignani A,Borzio F,Leandro G,Bono F,Asti M,Rossi S,Larghi A,Cerino A,Podda M,Mondelli MU.Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis:a prospective study.Hepatology 1997;25:754-758 被引量:1
  • 7[6]Benvegnu L,Chemello L,Noventa F,Fattovich G,Pontisso P,Alberti A.Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis.Cancer 1998; 83:901-909 被引量:1
  • 8[7]Mazzella G,Accogli E,Sottili S,Festi D,Orsini M,Salzetta A,Novelli V,Cipolla A,Fabbri C,Pezzoli A,Roda E.Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.J Hepatol 1996; 24:141-147 被引量:1
  • 9[8]Parkin DM,Stjernsward T,Muir CS.Estimates of the worldwide frequency of the twelve major cancers.Bull World Health Org 1984; 62:163-182 被引量:1
  • 10[9]McGlynn KA,Tsao L,Hsing AW,Devesa SS,Fraumeni JF Jr.International trends and patterns of primary liver cancer.Int J Cancer 2001; 94:290-296 被引量:1

共引文献47

同被引文献30

引证文献5

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部